Talha Badar: ASH23, a few selected CML abstracts to watch out at this year ASH

Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:

”Weekend review. ASH23, few selected CML abstracts to watch out at this year ASH.

447: Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. CHIP at the time of TKI cessation assoc. with better TFR. For the article click here.

445: Trial of Imatinib after Ponatinib Induction in the 1st line Rx CML-CP. Report of the First Therapeutic Sequence. Ponatinib 30 mg for 6 months followed by Imatinib to achieve better mol. response and TFR. For the article click here.

868: Asciminib +Imatinib, Nilotinib, or Dasatinib May be a Potential Rx Option in Pts with CML in CP/AP. Results from the Asciminib Phase 1 Study. ASC + ATP-competitive TKIs, while associated with a higher AE vs ASC monotherapy, demonstrated rapid efficacy in the enrolled pts.

869: Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study. For the article click here.

3164: Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib. For the article click here. 4 yrs OS ~ 85%.

4536: Sustained Efficacy and Safety with Asciminib after Almost 4 yrs f/u from Ascembl, a Phase 3 Study of Asciminib Vs Bosutinib ) for CML-CPafter ≥2 prior TKI: EOS Tx Update, Including Results from Switch Population. For the article click here.

446: Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial. For the article click here.”

Source: Talha Badar/Twitter